Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma

Cancer

Volumn 85, Issue 2, 1999, Pages 302-308

  Maehara, Yoshihiko ^a   Kakeji, Yoshihiro ^a   Watanabe, Akihiro ^a   Baba, Hideo ^a   Kusumoto, Hiroki ^a   Kohnoe, Shunji ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Anti p53 antibodies; Gastric cancer; P53 overexpression; Prognosis

Indexed keywords

ANTIBODY; MITOMYCIN; PROTEIN P53; UFT;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL FEATURE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; STOMACH CARCINOMA;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032890968     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990115)85:2<302::AID-CNCR6>3.0.CO;2-6     Document Type: Article

References (51)

1. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
2. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994;57:1-9.
3. Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
4. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69:409-16.
5. Carson DA, Lois A. Cancer progression and p53. Lancet 1995; 346:1009-11.
6. Volkman M, Müller M, Hofmann WJ, Meyer M, Hagelstein J, Räth U, et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology 1993;18:559-65.
7. Angelopoulou K, Diamandis EP, Sutherland DA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
8. Müller M, Volkmann M, Zentgraf H, Galle PR. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1994;330:865.
9. Crawford LV, Pim DC, Bulbrook, RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-8.
10. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168-74.
11. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52: 6380-4.
12. Caron de Fromentel C, May-Levin F, Mourisse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987;39:185-9.
13. Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993;53:3468-71.
14. von Brevern M-C, Hollstein MC, Cawley HM, De Benedetti VMG, Bennett WP, Liang L, et al. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 1996;56:4917-21.
15. Mundenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994;69:1115-9.
16. Peyrat J-P, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995;345:621-2.
17. Houbiers JGA, van der Burg SH, van de Watering LMG, Tollenaar RAEM, Braud A, van de Velde CJH, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995;72:637-41.
18. Lubin R, Zalcman G, Bouchet L, Trédaniel J, Legros Y, Cazals D, et al. Serum p53 antibodies as early markers of lung cancer. Nature Med 1995;1:701-2.
19. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdur AF, et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 1993;85:2012-8.
20. Rosenfeld MR, Malats N, Schramm L, Graus F, Cardenal F, Viñolas N, et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 1997; 89:381-5.
21. Banks L, Matlashewski M, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159: 529-34.
22. Porter PL, Gown AM, Kramp SG, Coltrerea MD. Widespread p53 overexpression in human malignant tumors. Am J Pathol 1992;140:145-53.
23. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Eric Blair G, et al. Prognostic value of p53 overexpression and c-Ki-rosgene mutations in colorectal cancer. Gastroenterology 1993;104: 57-64.
24. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85: 200-6.
25. Kawasaki S. A clinicopathological study on upward intramural extension of cancer of the stomach [in Japanese with English abstract]. Fukuoka Acta Medica 1975;66:1-23.
26. Bozzetti F, Bonfanti G, Bufalino R, Menotti V, Persano S, Andreola S, Doci R, Gennari L. Adequacy of margins of resection in gastrectomy for cancer. Ann Surg 1982;196:685-90.
27. Maehara Y, Okuyama T, Moriguchi S, Orita H, Kusumoto H, Korenaga D, et al. Prophylactic lymph node dissection in patients with advanced gastric cancer promotes increased survival time. Cancer 1992;70:392-5.
28. Korenaga D, Okamura T, Baba H, Saito A, Sugimachi K. Results of resection of gastric cancer extending to adjacent organs. Br J Surg 1988;75:12-5.
29. Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Part II. Histological classification of gastric cancer. Jpn J Surg 1981;11:127-39, 140-5.
30. Japanese Research Society for Gastric Cancer, editor. The general rules for gastric cancer study [in Japanese]. 12th ed. Tokyo: Kanehara & Co., Ltd., 1993.
31. Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K. Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995;75:1454-9.
32. Maehara Y, Okuyama T, Kakeji Y, Endo K, Yamamoto M, Sugimachi K. A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer. Br J Cancer 1995;71:999-1002.
33. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993;67:589-93.
34. Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita, M. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 1997;40:233-8.
35. Dixon WJ, editor. BMDP statistical software. Berkeley, CA: University of California Press, 1988.
36. Cox DR. Regression models and life tables. J R Statist Soc B 1972;34:187-220.
37. Diamandis EP. Oncogenes and tumor suppressor genes: new biochemical tests. Crit Rev Clin Lab Sci 1992;29:269-305.
38. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
39. Sorokine I, Ben-Mahrez K, Bracone A, Thierry D, Ishii S, Imamoto F, et al. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer 1991; 47: 665-9.
40. Ben-Mahrez K, Sorokine, I, Thierry D, Kawasumi T, Ishii S, Salmon R, et al. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 1990;46:35-8.
41. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Trédaniel J, Hirsch A, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993;53:5872-6.
42. Schlichtholz B, Trédaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994;69:809-16.
43. Green JA, Robertson W, Campbell IR, Jenkins J. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prevent 1995;19:151-5.
44. Komiya T, Hirashima T, Takada M, Masuda N, Yasumitsu T, Nakagawa K, et al. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 1997;17:3721-4.
45. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992;89:3439-42.
46. Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76: 720-6.
47. Caelles C, Helmberg A, Karin M. p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994:370:220-3.
48. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
49. Koechli OR, Schaer GN, Seifert B, Hornung R, Haller U, Eppenberger U, et al. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 1994;344:1647-8.
50. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995;87: 1254-6.
51. Chin K-V, Ueda K, Pastan I, Gottesman, MH. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 1992;255:459-62.